Form 4: Revelation Biosciences CEO Receives Significant Stock Grant

Revelation Biosciences CEO James Rolke acquired 390,614 shares of common stock through a restricted stock grant, increasing his direct beneficial ownership.

Summary

• James Rolke, Chief Executive Officer and Director of Revelation Biosciences, Inc. (REVB), acquired 390,614 shares of common stock.
• The transaction occurred on October 29, 2025, at a price of $1.28 per share.
• This acquisition was a Restricted Stock Grant issued under the company's 2021 Equity Incentive Plan.
• The granted shares will vest quarterly over one year from the grant date.
• Following this transaction, Rolke directly beneficially owns 400,660 shares of common stock.

Sentiment

Score: 7

Explanation: The filing reports a routine restricted stock grant to the CEO, which aligns management's interests with shareholders. This is generally viewed as a positive for corporate governance and long-term value creation, though it's a standard compensation event rather than a direct operational or financial performance indicator.

Positives

• CEO James Rolke received a significant restricted stock grant, aligning his interests with those of shareholders.
• The grant is part of the 2021 Equity Incentive Plan, indicating a structured approach to executive compensation and retention.

Future Outlook

The restricted stock grant will vest quarterly over one year from the grant date, indicating future vesting events and continued alignment of executive incentives.

Industry Context

Restricted stock grants are a common form of executive compensation in the biotechnology industry, designed to incentivize long-term performance, retain key talent, and align management's financial interests with those of shareholders.

Comparison to Industry Standards

• This type of restricted stock grant is a standard component of executive compensation packages across the biotechnology sector, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use equity incentives to attract and retain leadership.
• The vesting schedule of quarterly over one year is a common short-to-medium term incentive structure, similar to those seen in many growth-oriented biotech firms aiming to tie executive rewards to sustained performance.

Related Party Transactions

• CEO James Rolke received a restricted stock grant from Revelation Biosciences, Inc., which is a related party transaction as part of his compensation.

Stakeholder Impact

• Shareholders: The grant increases the alignment of the CEO's financial interests with shareholder value, potentially fostering long-term growth and performance.
• Employees: This transaction reflects standard executive compensation practices, which may influence broader compensation strategies within the company.

Next Steps

• The restricted stock grant will vest quarterly over one year from the grant date.

Key Dates

Recommendation

This Form 4 reports a standard restricted stock grant to the CEO, which is a routine compensation event. While it aligns management's interests with shareholders, it does not provide new material information regarding the company's operational performance or strategic outlook to alter an existing investment thesis.

Keywords

Revelation Biosciences, REVB, James Rolke, Form 4, Insider Transaction, Stock Grant, Restricted Stock, CEO Compensation, Equity Incentive Plan